Atebimetinib + GnP for Pancreatic Cancer

(MAPKeeper 301 Trial)

Recruiting at 5 trial locations

Overseen By Immuneering Study Team

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Immuneering Corporation

Disqualifiers: Inability to swallow, CNS metastases, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: Up to approximately 2 years

510 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.

I was diagnosed with metastatic pancreatic cancer at least 12 weeks ago.

I am fully active or can do light work despite my illness.

Exclusion Criteria

I cannot swallow pills or oral medications.

I have been diagnosed with a specific type of pancreatic cancer.

My cancer is only locally advanced and has not spread to distant parts of my body.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either atebimetinib with modified gemcitabine and nab-paclitaxel or standard gemcitabine and nab-paclitaxel

Up to approximately 2 years

Follow-up

Participants are monitored for safety, efficacy, and overall survival after treatment

Up to approximately 2 years

What Are the Treatments Tested in This Trial?

Interventions

• Atebimetinib
• GnP

How Is the Trial Designed?

Group I: Atebimetinib + mGnP Experimental Treatment 2 Interventions

Atebimetinib in combination with modified gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma

Group II: GnP Active Control 1 Intervention

Standard of care gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma

Who Is Running the Clinical Trial?

Immuneering Corporation

Lead Sponsor

Trials

2

Recruited

450+